The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://sahilpdwm112227.wikinewspaper.com/4297289/retatrutide_vs_tirzepatide_a_comparative_analysis